Search the Newsreel

ALIT Investors Have Opportunity to Lead Alight, Inc. Class Action

A class action lawsuit has been filed against Alight, Inc. (NYSE: ALIT) and its officers, alleging materially false and misleading statements were made to investors. The lawsuit claims that the company misrepresented its prospects under the new CEO, its commitment to capital return, its …

Align Technology Prevails in China Patent Infringement Action Against Angelalign

SAN JOSE, Calif. & TEMPE, Ariz., August 12, 2026--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a …

Angelalign Technology (SEHK:6699) Lifts Earnings Guidance, Is The Premium Already Priced In?

Align Names Noel Kilcooley CTO to Lead AI and Technology Strategy

Align has appointed Noel Kilcooley as Chief Technology Officer, entrusting him with the company's technology strategy, AI initiatives, cybersecurity, and compliance. This move positions Align to support clients navigating complex infrastructure demands driven by AI adoption. Kilcooley, a 25-year veteran of the company, will …

Alight and eMed Join Forces to Expand Access to GLP-1 Therapies for Employers, Advancing Population and Workforce Health

DEERFIELD, Ill., August 11, 2026--(BUSINESS WIRE)--Alight, Inc. (NYSE: ALIT), a leading benefits administration provider of health, wealth and leave solutions, today announced the addition of eMed Population Health, Inc., a platform for employer-sponsored preventative health management, to the Alight Partner Network. The collaboration will …

5 Revealing Analyst Questions From Alight’s Q2 Earnings Call

5 Revealing Analyst Questions From Alight's Q2 Earnings Call Alight's second quarter was marked by better-than-expected revenue and adjusted profitability, but the market reacted negatively, likely reflecting investor concerns about the company's declining sales and underlying renewal trends. Management highlighted that project revenue growth …

Alignment Healthcare upgraded to Buy after strong Q2 results and 40%+ upside potential despite valuation drop.

Alignment Healthcare has been upgraded from Hold to Buy following a significant valuation-driven price drop, despite strong Q2 operational performance including record-low medical benefits ratio and substantial membership and EBITDA growth. The company also raised its full-year guidance, with the stock currently trading at …

Weekly Recap: Q2 2026 revenue decline and ALIT integrates leave solutions

Alight, Inc. (NYSE:ALIT) reported a Q2 2026 revenue decline to $511M year-over-year, alongside a $10M net loss, though recurring revenue remained high at approximately 92% and SG&A decreased. The company also provided guidance for Q3 and the full year, while integrating new leave solutions …

Contravisory Investment Management Inc. Makes New $1.11 Million Investment in Align Technology, Inc. $ALGN

Contravisory Investment Management Inc. recently invested $1.11 million in Align Technology (NASDAQ:ALGN) by acquiring 6,557 shares in the second quarter. This move is part of broader institutional interest, with hedge funds collectively owning 88.43% of the company. Align Technology has reported strong financial results, …

Alignment healthcare CEO John Kao sells $4.14m in company stock

John E. Kao, CEO of Alignment Healthcare, sold 298,000 shares of company stock for over $4.1 million, executed under a Rule 10b5-1 trading plan. This sale comes as the stock trades near its 52-week low and after mixed Q2 2026 financial results, which included …

Insider Selling: Alignment Healthcare (NASDAQ:ALHC) CEO Sells 298,000 Shares of Stock

Alignment Healthcare (NASDAQ:ALHC) CEO John Kao sold 298,000 shares of the company's stock for approximately $4.14 million, reducing his direct ownership by 27.37%. This transaction occurred despite the company exceeding Q2 earnings expectations with $0.17 EPS and a 31.6% increase in revenue. Analysts maintain …

H.C. Wainwright reiterates Aligos stock rating on HBV progress

H.C. Wainwright reaffirmed a Buy rating and $50 price target for Aligos Therapeutics Inc. (NASDAQ:ALGS) following positive updates on its chronic hepatitis B virus infection treatments, including breakthrough therapy designation for pevifoscorvir sodium in China and complete enrollment of the Phase 2 B-SUPREME trial. …

Did Align’s Expanded 2026 Buyback and Board Refresh Just Shift Align Technology's (ALGN) Investment Narrative?

Align Technology recently reported Q2 2026 results, showing increased sales but softer Q3 guidance and outlining impacts from restructuring and legal charges. In conjunction with Elliott Investment Management, Align committed to new board members, a strategic review, and an expanded 2026 share repurchase plan …

Kaplan Fox Announces an Investigation Into Alignment Healthcare

Kaplan Fox & Kilsheimer LLP has announced an investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) regarding potential securities law violations. This follows news of a whistleblower complaint alleging "accounting irregularities" that artificially inflated the company's financial results, specifically Adjusted EBITDA. Following this revelation, Alignment …

Kaplan Fox & Kilsheimer LLP is Investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for Possible Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for potential securities law violations. This follows a whistleblower complaint alleging "accounting irregularities" that "artificially inflated" the company's financial results and a key non-GAAP metric, Adjusted EBITDA. Following the news of the …

Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS)

Align Technology, Inc. $ALGN Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly reduced its stake in Align Technology, Inc. (NASDAQ:ALGN) by 36.2% in the second quarter, selling over 358,000 shares. Despite this, other institutional investors like Capital International Investors and Invesco Ltd. increased their holdings. Align Technology reported strong Q2 earnings, …

Janus Henderson Group PLC Has $5.28 Million Holdings in Align Technology, Inc. $ALGN

Janus Henderson Group PLC reduced its stake in Align Technology, Inc. by 25.4% in the first quarter, now holding 30,791 shares valued at $5.28 million. Align Technology exceeded Q1 earnings expectations, reporting $2.64 EPS and $1.06 billion in revenue, and has a "Moderate Buy" …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alignment Healthcare, Inc. - ALHC

Pomerantz LLP is investigating potential securities fraud claims against Alignment Healthcare, Inc. (ALHC) following allegations by a former executive of "accounting irregularities." The whistleblower complaint suggests the company artificially inflated its financial results, including Adjusted EBITDA, by misclassifying operating expenses as capital expenditures. This …

Lake Street Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $45

Lake Street has reiterated its Buy rating on Aligos Therapeutics (ALGS.US) and maintained its target price at $45. This suggests continued confidence in the company's financial prospects and growth potential from the analyst firm.

How Investors May Respond To Alignment Healthcare (ALHC) Raising 2026 Revenue Guidance After Strong Q2 Results

Align Technology Expanding its Global Operations

Align Technology announced plans to open its first manufacturing facility in Hyderabad, India, by next year. This expansion, involving a $200 million investment and creating over 300 jobs, aims to bring operations closer to high-growth markets like India and enhance supply chain resilience. The …

Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary

Aligos Therapeutics, Inc. has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief update on the company's financial performance. Readers are encouraged to access the full report on TradingView for complete details.

Alignment Healthcare, Inc. (ALHC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alignment Healthcare, Inc. (ALHC) following allegations of accounting irregularities that artificially inflated the company's financial results. A former executive filed a whistleblower complaint, leading to a significant drop in Alignment's stock price on July …

Kaplan Fox Encourages Investors of Alignment Healthcare, Inc. (NASDAQ: ALHC) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. (NASDAQ: ALHC) after news emerged of a whistleblower complaint. The complaint alleges accounting irregularities that artificially inflated the company's financial results and executive compensation. Following this news, Alignment Healthcare's stock …

Lowey Dannenberg, P.C. is Investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for Potential ...

Lowey Dannenberg P.C. is investigating Alignment Healthcare, Inc. (NASDAQ: ALHC) for potential federal securities law violations. This follows a whistleblower lawsuit alleging the company manipulated its finances by misclassifying operating expenses as capital expenditures to inflate its adjusted EBITDA. The lawsuit claims this artificial …

Alight (ALIT) Stock Sinks As Margin Pressure Drowns Out Cash Strength

Alight's stock (ALIT) dropped 16% after Q2 2026 earnings revealed significant profit pressure, with adjusted EBITDA at US$92m on US$511m revenue, despite a narrowed net loss year-over-year. Recurring revenue also declined, raising concerns for bears who question commercial execution and earnings quality, although the …

Align Technology Inc (ALGN) Stock Down 3.2% -- Now Undervalued? GF Score: 89/100

Align Technology Inc (ALGN) shares recently dropped by 3.2%, bringing its current price to $169.08. Despite this, the stock is considered undervalued with a GF Value™ estimate of $228.51, and boasts a strong GF Score™ of 89/100, indicating robust fundamentals. While profitability and valuation …

How Alight Inc. Class A (ALIT) Affects Rotational Strategy Timing

This article analyzes Alight Inc. Class A (ALIT) using AI models to provide insights for rotational strategy timing. Key findings indicate weak sentiment across all horizons, supporting a short bias, despite compelling upside potential due to no resistance levels above the current price. Three …

Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary

Aligos Therapeutics reported its second-quarter 2026 results, showing a net loss of $(1.50)M and diluted EPS of $(0.14), which is a narrower loss compared to the previous year. The company's revenue momentum was driven by $27.8M in license revenue, primarily from an exclusive Greater …

Align Technology Inc. stock underperforms Thursday when compared to competitors

Align Technology Inc. (ALGN) stock declined by 3.29% to $169.08 on Thursday, underperforming the broader market. This drop occurred during a session where the S&P 500 Index fell 0.18% and the Dow Jones Industrial Average dropped 0.85%, ending a three-day winning streak for the …

ALHC INVESTOR ALERT: Alignment Healthcare, Inc. (NASDAQ: ALHC) Investors Urged to Contact Hagens Berman; Investigation Opened Following Disappointing Second-Quarter Results and Whistleblower Allegations

Hagens Berman Sobol Shapiro LLP has initiated an investigation into Alignment Healthcare, Inc. (NASDAQ: ALHC) following disappointing second-quarter 2026 financial guidance and serious whistleblower allegations. The investigation focuses on potential securities law violations, specifically concerning whether the company misled investors about profitability and expense …

Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com

This article reports on an SEC Form 8K filing by Aligos Therapeutics Inc. on August 6th. The filing indicates a significant event or change for the company, as reflected by its stock symbol ALGS, which showed a 16.24% increase.

Is ALHC Stock a Buy as Fast Growth Clashes With Premium Valuation?

Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash

Aligos Therapeutics announced its Q2 2026 financial results, reporting $27.8 million in licensing revenue and a net loss of $1.5 million. The company ended the quarter with $30.4 million in cash, excluding a $25 million upfront payment received in July 2026. Key business developments …

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Aligos Therapeutics reported significant business progress and financial results for Q2 2026, highlighting advances in its liver and viral disease pipeline. Key achievements include the completion of enrollment for the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV, its Breakthrough Therapy Designation …